Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Targeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of Chronic Prurigo Treatment

Author(s): Aleksandra A. Stefaniak and Jacek C. Szepietowski*

Volume 30, Issue 23, 2024

Published on: 22 May, 2024

Page: [1787 - 1790] Pages: 4

DOI: 10.2174/0113816128300373240514072201

Price: $65

Next »
[1]
Pereira MP, Ständer S. How to define chronic prurigo? Exp Dermatol 2019; 28(12): 1455-60.
[http://dx.doi.org/10.1111/exd.13972] [PMID: 31102542]
[2]
Ständer S, Pereira MP, Berger T, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch 2020; 5(4): e42-2.
[http://dx.doi.org/10.1097/itx.0000000000000042]
[3]
Labib A, Ju T, Vander Does A, Yosipovitch G. Immunotargets and therapy for prurigo nodularis. ImmunoTargets Ther 2022; 11: 11-21.
[http://dx.doi.org/10.2147/ITT.S316602] [PMID: 35502157]
[4]
Campion M, Smith L, Gatault S, Métais C, Buddenkotte J, Steinhoff M. Interleukin‐4 and interleukin‐13 evoke scratching behaviour in mice. Exp Dermatol 2019; 28(12): 1501-4.
[http://dx.doi.org/10.1111/exd.14034] [PMID: 31505056]
[5]
Müller S, Zeidler C, Ständer S. Chronic prurigo including prurigo nodularis: New insights and treatments. Am J Clin Dermatol 2024; 25(1): 15-33.
[http://dx.doi.org/10.1007/s40257-023-00818-z] [PMID: 37717255]
[6]
Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 2017; 171(1): 217-228.e13.
[http://dx.doi.org/10.1016/j.cell.2017.08.006] [PMID: 28890086]
[7]
Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29(5): 1180-90.
[http://dx.doi.org/10.1038/s41591-023-02320-9] [PMID: 37142763]
[8]
Gao Z, Dou Y, Zhao P, Wang CJ, Zhang J. Successful treatment of prurigo nodularis by dupilumab: Report of 24 patients. Dermatology 2023; 239(4): 658-63.
[http://dx.doi.org/10.1159/000529965] [PMID: 37011607]
[9]
Fang HY, Lian CH. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real‐life observational study. J Dermatol 2023; 50(8): 1084-7.
[http://dx.doi.org/10.1111/1346-8138.16803] [PMID: 37088954]
[10]
Husein-ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: A systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat 2022; 33(3): 1547-53.
[http://dx.doi.org/10.1080/09546634.2020.1853024] [PMID: 33200955]
[11]
Zhang Z, Li S, Wang Y, Zhao J. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis. An Bras Dermatol 2023; 98(4): 440-8.
[http://dx.doi.org/10.1016/j.abd.2022.09.008] [PMID: 36966024]
[12]
Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med 2020; 382(8): 706-16.
[http://dx.doi.org/10.1056/NEJMoa1908316] [PMID: 32074418]
[13]
Ständer S, Yosipovitch G, Lacour JP, et al. Nemolizumab efficacy in prurigo nodularis: Onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol 2022; 36(10): 1820-5.
[http://dx.doi.org/10.1111/jdv.18377] [PMID: 35766128]
[14]
Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 2023; 389(17): 1579-89.
[http://dx.doi.org/10.1056/NEJMoa2301333] [PMID: 37888917]
[15]
Sofen H, Bissonnette R, Yosipovitch G, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: A randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine 2023; 57: 101826.
[http://dx.doi.org/10.1016/j.eclinm.2023.101826] [PMID: 36816342]
[16]
Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D. Benralizumab for chronic spontaneous urticaria. N Engl J Med 2020; 383(14): 1389-91.
[http://dx.doi.org/10.1056/NEJMc2016395] [PMID: 32997916]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy